K

Karolinska Development AB
STO:KDEV

Watchlist Manager
Karolinska Development AB
STO:KDEV
Watchlist
Price: 1.208 SEK 0.17% Market Closed
Market Cap: 322.9m SEK
Have any thoughts about
Karolinska Development AB?
Write Note

Relative Value

The Relative Value of one KDEV stock under the Base Case scenario is 0.055 SEK. Compared to the current market price of 1.208 SEK, Karolinska Development AB is Overvalued by 95%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

KDEV Relative Value
Base Case
0.055 SEK
Overvaluation 95%
Relative Value
Price
K
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
69
vs Industry
3
Median 3Y
218.2
Median 5Y
208.4
Industry
2.6
Forward
159.8
vs History
vs Industry
34
Median 3Y
-4.1
Median 5Y
2.1
Industry
22.3
Forward
-12
vs History
vs Industry
Median 3Y
-15.4
Median 5Y
-15
Industry
17.5
vs History
vs Industry
Median 3Y
-15
Median 5Y
-14.7
Industry
24.8
vs History
98
vs Industry
78
Median 3Y
0.4
Median 5Y
0.5
Industry
2.1
vs History
57
vs Industry
3
Median 3Y
171.4
Median 5Y
152.9
Industry
2.7
Forward
130.5
vs History
vs Industry
Median 3Y
0
Median 5Y
0
Industry
5.3
vs History
vs Industry
Median 3Y
-20.5
Median 5Y
-13.5
Industry
13.4
Forward
-8.7
vs History
vs Industry
Median 3Y
-19.6
Median 5Y
-13.5
Industry
16.8
Forward
-8.4
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-10.4
Industry
15.9
vs History
vs Industry
Median 3Y
-9.8
Median 5Y
-10.4
Industry
18.5
vs History
95
vs Industry
81
Median 3Y
0.3
Median 5Y
0.4
Industry
1.9

Multiples Across Competitors

KDEV Competitors Multiples
Karolinska Development AB Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
SE
Karolinska Development AB
STO:KDEV
326m SEK 171.3 -57.7 -12.1 -11.6
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
793.7B USD 20.4 108.1 54.1 60.6
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 13.1 37.5 25 28.7
US
Johnson & Johnson
NYSE:JNJ
385.5B USD 4.4 26.3 12.7 16.5
US
Merck & Co Inc
NYSE:MRK
260.6B USD 4.2 19 12.9 15.8
CH
Roche Holding AG
SIX:ROG
213.6B CHF 3.6 18.6 10.4 12.4
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP 4.5 34.5 170.6 255.7
CH
Novartis AG
SIX:NOVN
183.5B CHF 4.3 13.1 10.4 15.4
US
Pfizer Inc
NYSE:PFE
161.4B USD 2.7 38 11.1 16.7
P/E Multiple
Earnings Growth
SE
K
Karolinska Development AB
STO:KDEV
Average P/E: 36.9
Negative Multiple: -57.7
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
108.1
454%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
37.5
89%
US
Johnson & Johnson
NYSE:JNJ
26.3
-22%
US
Merck & Co Inc
NYSE:MRK
19
7 426%
CH
Roche Holding AG
SIX:ROG
18.6
30%
UK
AstraZeneca PLC
LSE:AZN
34.5
175%
CH
Novartis AG
SIX:NOVN
13.1
19%
US
Pfizer Inc
NYSE:PFE
38
712%

See Also

Discover More
Back to Top